0
Products in the cart
Total:
Information block example
Currency
English Support
Request a call
Working hours:
Пн-Пт 9:00—23:00;
Сб-Вс 10:00-20:00

Soranib

Soranib (Sorafenib)

Soranib is a anticancer drug and indicated for the treatment of some condition as Advanced renal cell carcinoma Hepatocellular carcinoma Metastatic thyroid carcinoma

Feature
Brand name:
Soranib
Active substance:
Sorafenib 200mg
Manufacturer:
Cipla Ltd
Packaging:
120 Tablets
Product form:
Tablet
In stock
Active substance: Sorafenib
0 $
Available options:
Amount:
To wishlist
Compared
Consulting:+91(994)0472902
Description

DESCRIPTION

Sorafenib sold under the brand name Soranib. Soranib belongs to the group of tyrosine kinase inhibitor or inhibitor of angiogensis. The drug is a type of targeted therapy Soranib is a prescription drug used under the supervision of health care provider.

INDICATION

Soranib is a anticancer drug and indicated for the treatment of some condition as Advanced renal cell carcinoma Hepatocellular carcinoma Metastatic thyroid carcinoma

WORKS IN THE BODY

Soranib includes in deficiency of tumor cell multiplication Soranib interfere with multiple intracellular and cell surface kinase These enzymes are specific for tumor cell signaling, angiogenesis and apoptosis. Soranib causes to reduce the blood flow to the cancer cells By prohibiting these enzymes (kinase), genetic transcription includes in cell proliferation and angiogenesis is blocked.

ADME

ABSORPTION

The Soranib bioavailability is 38 to 49% The time to peak serum concentration in 3 hours. High fat meals may decrease the bioavailability of Sorafenib

DISTRIBUTION

The drug Soranib has Human plasma protein bound is 99.5%

METABOLISM

In liver Soranib is highly metabolized, it go through oxidative metabolism with the help of CYP3A4 and Glucuronidation by UGT1A9 The main flowing metabolite in serum is pyridine N oxide

ELIMINATION

The dose excreted via feces 77% The dose excreted via urine 19% as glucuronidated metabolites Soranib half life is 25 to 48 hours

DOSAGE MANAGEMENT

In Renal Cell Carcinoma

The dose of Soranib is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal

Thyroid Carcinoma

The dose of Soranib is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal

Hepatocellular Carcinoma

The usual dose of Soranib is given as 400mg should be taken orally as twice daily for at least one hour before or two hours after the meal.

SAFETY PRECAUTIONS & CONTRAINDICATION

Soranib should not be used, in case of lung cancer, being treated with platinum containing chemo drugs and taxol drugs Soranib able to cause heart problems, stop the medicine in case of dizziness, fainting, sweating or shortening of breath Soranib causes severe bleeding; care should be taken while getting Soranib Stop the Tablet Soranib in case of;

blood in urine or stools, blood while coughing, Vaginal bleeding Hemorrhage risk QT prolongation. High occurrence of skin toxicity and rashes. Impairs exogenous thyroid suppression. Hypersentivity to the drug and any product of expicients.

SIDE EFFECTS

Lymphopenia Neutropenia Hemorrhage Hypertension Neuropathy Anorexia Headache Joint pain Congestive heart failure Acute renal failure Angiodema arrhythmia Interstitial lung disease Post marketing reports: Hypersensitivity reactions: angioedema, anaphylactic reaction Hepatobiliary disorders: hepatitis, hepatic failure and death Musculoskeletal: rhabdomyolysis, osteonecrosis of the jaw Pulmonary: interstitial lung disease

DRUG INTERACTION

Interaction of Soranib with Rifampin a strong CYP3A4 inducer, administered at a dose of 600mg single use for 5 days with Soranib causes decrease AUC of Sorafenib Interaction with neomycin will reduce the AUC of Sorafenib Interaction with acetaminophen will raises the hepatoxicity effect of Sorafenib Interaction with Bevacizumab will increase the toxic effect of Sorafenib

 PREGNANCY

Category D: Soranib can harm to an fetus and cause injury and even death to the unborn baby if you treatment during the 2nd and 3rd trimesters of pregnancy, pregnant women do not use the Soranib medicine without the knowledge of your doctor.

LACTATION

The medicine passes into breast milk is not known or could harm a new born baby. Do not use Soranib medication, if your breast feeding.

STORAGE 

Soranib should be store at 25°C (77°F); excursion are allowed between 15°C and 30oC (59°F and 86°F) Protect from moisture, heat and light

MISSED DOSE

If patient missed to take Soranib tablet, they may get advice from medical practitioner (consult) for administration of the missed dose within the time Or the missed dose should be skipped and follow the next dosing schedule Do not have double the dose.

Feature
Brand name
Soranib
Active substance
Sorafenib 200mg
Manufacturer
Cipla Ltd
Packaging
120 Tablets
Product form
Tablet
Strength
200mg
Soranib отзывы
Add a comment
0

We use cookies to make the site better for you! Note: We strongly encourage you to talk with your health care professional about your specific medical condition and treatments. The information contained in this website is meant to be helpful and educati
MEDICAL DISCLAIMERAll the contents present on the website are solely for informational purposes. Thereby, the information on the website isn’t meant to be a substitute for professional medical advice, treatment, and/or diagnosis. Please seek professiona